Objective: Haematuria, which is the most common presenting symptom in bladder cancer (BCa), may also occur with the effect of some medications. The aim of this study was to evaluate the role of antiplatelet (AP) drugs in the diagnosis of BCa. Material and Methods: Patients who applied to our urology clinic between January 2013 and December 2018 and underwent transurethral resections (TURs) for primary BCa were reviewed retrospectively. Patients were divided into 2 groups according to AP drug use (group 1: no AP therapy, group 2: recieving AP therapy). The groups were compared in terms of demographic data, complaint of admission, smoking status, tumor size, multifocality, pathologic stage and grade, and BCa risk group. Results: A total of 290 patients, 233 in Group 1 and 57 in Group 2, were included in the study. The mean age of the patients was 68.69 ± 9.48 years and 246 of (84.8%) patients were male. There was no statistically significant difference between groups in terms of age, sex, presenting symptom, smoking status, tumor size, multifocality, pathological stage and grade and BCa risk groups. Conclusion: According to our results, AP drug use in BCa was found to have no effect on pathologic results, tumor size, multifocality and presenting symptom at the first diagnosis and can not be conclude that cause early or delayed diagnosis in BCa
Amaç: Mesane kanserinde en sık görülen semptom olan hematüri bazı ilaçların etkisiyle de ortaya çıkabilir. Bu çalışmanın amacı antiplatelet (AP) ilaçların mesane kanseri tanısındaki rolünü değerlendirmektir. Gereç ve Yöntemler: Üroloji kliniğimize Ocak 2013 - Aralık 2018 tarihleri arasında başvuran ve primer mesane kanseri tanısı ile transüretral re-zeksiyon (TUR) uygulanan hastalar retrospektif olarak incelendi. Hastalar AP ilaç kullanımına göre 2 gruba ayrıldı (grup 1: AP tedavisi almayan, grup 2: AP tedavisi alan). Gruplar demografik ve-riler, başvuru şikayeti, sigara içme durumu, tümör büyüklüğü, multifokalite, patolojik evre ve derece ile mesane kanseri risk grubu açısından karşılaş-tırıldı. Bulgular: Çalışmaya; grup 1’de 233, grup 2’de 57 olmak üzere toplam 290 hasta alındı. Hasta-ların yaş ortalaması 68,69 ± 9,48 yıldı ve 246’sı (% 84,8) erkekti. Gruplar arasında yaş, cinsiyet, başvuru semptomu, sigara içme durumu, tümör büyüklüğü, multifokalite, patolojik evre, derece ve mesane kanseri risk grubu açısından istatistiksel olarak anlamlı fark yoktu. Sonuç: Sonuçlarımıza göre, mesane kanse-rindeki AP ilaç kullanımının ilk tanıda patolojik sonuçlar, tümör boyutu, multifokalite ve başvuru semptomu üzerinde hiçbir etkisinin olmadığı ve mesane kanserinde erken veya gecikmiş tanıya neden olduğu sonucuna varılamayacağı tespit edildi.
1. Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLO-BOCAN sources and methods. Int J Cancer 2019;144:1941-1953.
2. Kamat AM, Hahn NM, Efstathiou JA, et al. Bladder cancer. Lancet 2016;388:2796-2810.
3. DeGeorge KC, Holt HR, Hodges SC. Bladder Cancer: Di-agnosis and Treatment Am Fam Physician 2017;96:507-514.
4. Babjuk M, Böhle A, Burger M, et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Blad-der: Update 2016. Eur Urol 2017;71:447-461.
5. Davis R, Jones JS, Barocas DA, et al.; American Urological Association. Diagnosis, evaluation and follow-up of asy-mptomatic microhematuria (AMH) in adults: AUA guide-line. J Urol 2012;188:2473-2481.
6. Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007;178:2314-2330.
7. Golin AL, Howard RS. Asymptomatic microscopic hema-turia. J Urol 1980;124:389-391.
8. Ngo B, Papa N, Perera M, Bolton D, Sengupta S. Bladder cancer diagnosis during haematuria investigation - impli-cations for practice guidelines. BJU Int 2017;119:53-54.
9. Sharp VJ, Barnes KT, Erickson BA. Assessment of asymp-tomatic microscopic hematuria in adults. Am Fam Physici-an 2013;88:747-754.
10. Baigent C, Blackwell L, Collins R, et al. Aspirin in the pri-mary and secondary prevention of vascular disease: colla-borative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849–1860.
11. Shehab N, Lovegrove MC, Geller AI, Rose KO, Weidle NJ, Budnitz DS. US emergency department visits for outpatient adverse drug events, 2013-2014. JAMA 2016;316:2115-2125. 12. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with war-farin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955-962.
13. Gaist D, García Rodríguez LA, Hellfritzsch M, et al. Associ-ation of antithrombotic drug use with subdural hematoma risk. JAMA 2017;317:836-846.
14. de Martino M, Shariat SF, Hofbauer SL, et al. Aurora A ki-nase as a diagnostic urinary marker for urothelial bladder cancer. World J Urol 2015;33:105-110.
15. Karaoglu I, van der Heijden AG, Witjes JA. The role of urine markers, white light cystoscopy and fluorescen-ce cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancer. World J Urol 2014;32:651-659.
16. Sayyid RK, Sayyid AK, Klaassen Z, et al. Replacing sur-veillance cystoscopy with urinary biomarkers in followup of patients with non-muscle-invasive bladder cancer: Pa-tients’ and urologic oncologists’ perspectives. Can Urol As-soc J 2018;12:E210-E218.
17. Beukers W, van der Keur KA, Kandimalla R, et al. FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study. J Urol 2017;197:1410-1418.
18. Todenhöfer T, Hennenlotter J, Guttenberg P, et al. Prog-nostic relevance of positive urine markers in patients with negative cystoscopy during surveillance of bladder cancer. BMC Cancer 2015;15:155.
19. Schmitz-Dräger BJ, Droller M, Lokeshwar VB, et al. Mo-lecular markers for bladder cancer screening, early diag-nosis, and surveillance: the /ICUD consensus. Urol Int 2015;94:1-24.
20. Pashos CL, Botteman MF, Laskin BL, Redaelli A. Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract 2002;10:311–322.
21. Nathan AS, Sen S, Yeh RW. The risk of bleeding with the use of antiplatelet agents for the treatment of cardiovascu-lar disease. Expert Opin Drug Saf 2017;16:561-572.
22. Wallis CJD, Juvet T, Lee Y, et al. Association Between Use of Antithrombotic Medication and Hematuria-Related Complications. JAMA 2017;318:1260-1271.
23. Bhatt NR, Davis NF, Nolan WJ, et al. Incidence of Visible Hematuria Among Antithrombotic Agents: A Systematic Review of Over 175,000 Patients. Urology 2018;114:27-32.
24. Goli RR, Contractor MM, Nathan A, Tuteja S, Kobayashi T, Giri J. Antiplatelet Therapy for Secondary Prevention of Vascular Disease Complications. Curr Atheroscler Rep 2017;19:56.
25. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a “set up” for vascular disease. Circulation 2003;107:139-146.
26. Savji N, Rockman CB, Skolnick AH, et al. Association between advanced age and vascular disease in different ar-terial territories: a population database of over 3.6 million subjects. J Am Coll Cardiol 2013;61:1736-1743.
27. Hajar R. Risk Factors for Coronary Artery Disease: Histo-rical Perspectives. Heart Views 2017;18:109-114. 28. Picozzi S, Marenghi C, Ricci C, Bozzini G, Casellato S, Carmignani L. Risks and complications of transurethral resection of bladder tumor among patients taking an-tiplatelet agents for cardiovascular disease. Surg Endosc 2014;28:116-121.
29. Prader R, De Broca B, Chevallier D, Amiel J, Durand M. Outcome of Transurethral Resection of Bladder Tumor: Does Antiplatelet Therapy Really Matter? Analysis of a Retrospective Series. J Endourol 2017;31:1284-1288.
30. Moschini M, Karnes RJ, Suardi N, et al. Potential Effect of Antiplatelet and Anticoagulant Therapy on the Timing of the Diagnosis of Bladder Cancer. Clin Genitourin Cancer 2016;14:e245-250.